<DOC>
	<DOCNO>NCT01295112</DOCNO>
	<brief_summary>This study design determine addition Ozurdex® bevacizumab ( Avastin® ) eye injection reduces need repeat bevacizumab eye injection patient nonischemic central retina vein occlusion .</brief_summary>
	<brief_title>Effect Ozurdex® 0.7 mg Improvement Efficacy Bevacizumab Central Retinal Vein Occlusion</brief_title>
	<detailed_description>This multicenter clinical study design determine addition Ozurdex® injection bevacizumab ( Avastin® ) eye injection reduces need repeat bevacizumab eye injection patient nonischemic central retina vein occlusion .</detailed_description>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1. male female subject ( age 18 old ) ; 2. provide write informed consent sign/date health information release ; 3. woman childbearing potential must willing practice effective contraception duration study . 1. systemic disease clinical evidence condition would make subject , opinion investigator , unsuitable study could potentially confound study result ; 2. use systemic steroid within 1 month prior Baseline Visit ( Visit 1 ) anticipate use time study ( inhale intranasal steroid allow ) ; 3. sit systolic blood pressure equal great 160 mmHg diastolic blood pressure equal great 100 mmHg Baseline Visit ( Visit 1 ) ; 4. use warfarin , heparin , enoxaparin similar anticoagulant within 2 week prior Baseline Visit ( Visit 1 ) anticipate use time study ; 5. know allergy hypersensitivity study medication component ; 6. previous enrollment Ozurdex® clinical trial previous use Ozurdex® implant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>